Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for IOL Chemicals And Pharmaceuticals's Equity-to-Asset or its related term are showing as below:
NSE:IOLCP'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.23 Med: 0.7 Max: 0.78
Current: 0.7
During the past 13 years, the highest Equity to Asset Ratio of IOL Chemicals And Pharmaceuticals was 0.78. The lowest was 0.23. And the median was 0.70.
NSE:IOLCP's Equity-to-Asset is ranked better than 64.02% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 0.61
vs NSE:IOLCP: 0.70
IOL Chemicals And Pharmaceuticals (NSE:IOLCP) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
IOL Chemicals And Pharmaceuticals Equity-to-Asset Related Terms
IOL Chemicals And Pharmaceuticals Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IOL Chemicals And Pharmaceuticals Equity-to-Asset Chart
NSE:IOLCP vs ZTS, UTHR: Equity-to-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, IOL Chemicals And Pharmaceuticals's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IOL Chemicals And Pharmaceuticals Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, IOL Chemicals And Pharmaceuticals's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where IOL Chemicals And Pharmaceuticals's Equity-to-Asset falls into.
IOL Chemicals And Pharmaceuticals Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IOL Chemicals And Pharmaceuticals (NSE:IOLCP) has a Equity-to-Asset of 0.70 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on IOL Chemicals And Pharmaceuticals and its competitors. This is near median its historical median of 0.70. Over the past decade, IOL Chemicals And Pharmaceuticals' Equity-to-Asset has ranged from 0.23 to 0.78. According to the industry distribution chart, IOL Chemicals And Pharmaceuticals ranks #362 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 36%.
Is IOL Chemicals And Pharmaceuticals' Equity-to-Asset too high?
IOL Chemicals And Pharmaceuticals' current Equity-to-Asset of 0.70 is near median its 10-year median of 0.70. Over the past 10 years, this metric has ranged from a low of 0.23 to a high of 0.78. The Drug Manufacturers industry median Equity-to-Asset is 0.61. IOL Chemicals And Pharmaceuticals' value of 0.70 is 14.8% above this industry median. Based on the distribution chart, IOL Chemicals And Pharmaceuticals ranks #362 out of 1006 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, IOL Chemicals And Pharmaceuticals has a GF Score™ of 64/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does IOL Chemicals And Pharmaceuticals' Equity-to-Asset compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, IOL Chemicals And Pharmaceuticals ranks #362 out of 1006 companies for Equity-to-Asset. This puts IOL Chemicals And Pharmaceuticals in the upper half of its industry. The industry median Equity-to-Asset is 0.61. IOL Chemicals And Pharmaceuticals' value of 0.70 is 14.8% above this benchmark. Historically, IOL Chemicals And Pharmaceuticals' own Equity-to-Asset has ranged from 0.23 to 0.78 over the past decade. While the company's 10-year median is 0.70 vs. the industry median of 0.61, IOL Chemicals And Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.61, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IOL Chemicals And Pharmaceuticals's current Equity-to-Asset of 0.70 is 14.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on IOL Chemicals And Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IOL Chemicals And Pharmaceuticals's current Equity-to-Asset is 0.70, which is near median its own 10-year median of 0.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IOL Chemicals And Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, IOL Chemicals And Pharmaceuticals (NSE:IOLCP) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹94.57, compared to a current price of ₹148.23 — trading 56.7% above its estimated fair value. The current Equity-to-Asset is 0.70, which is near median its 10-year median of 0.70 and 14.8% above the Drug Manufacturers industry median of 0.61. IOL Chemicals And Pharmaceuticals' overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For IOL Chemicals And Pharmaceuticals (NSE:IOLCP), the current Equity-to-Asset is 0.70 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IOL Chemicals And Pharmaceuticals (NSE:IOLCP) Overvalued in 2026?
Based on GuruFocus' analysis, IOL Chemicals And Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹148.23 is trading 56.7% above its estimated GF Value™ of ₹94.57.
GuruFocus considers IOL Chemicals And Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for NSE:IOLCP:
Equity-to-Asset: 0.70 (near median its 10-year median of 0.70)
GF Value™: ₹94.57 vs. price of ₹148.23 (56.7% above fair value)
Industry Position: 14.8% above the Drug Manufacturers median (#362 of 1006)
No single metric tells the full story. See the NSE:IOLCP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
IOL Chemicals And Pharmaceuticals Business Description
IOL Chemicals And Pharmaceuticals Ltd is an India-based pharmaceutical company. The primary activity of the group is the manufacturing and sale of drugs and organic chemicals. The business activity is functioned through the Chemicals and Pharmaceutical segments. The Chemicals segment produces and sells chemicals such as Ethyl Acetate, Acetic Anhydride, Acetyl Chloride, Mono Chloro Acetic Acid, and Iso Butyl benzene, whereas the Pharmaceutical segment produces and sells various active pharmaceutical ingredients such as Ibuprofen, Metformin, Fenofibrate, Lamotrigine, and others. It derives prime revenue from the Pharmaceutical segment. Geographically, the group's products are sold in both the Indian and international markets.
64GF Score
Get the complete analysis for NSE:IOLCP
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:IOLCP has been successfully added to your 
